Home    Contact    Sitemap    Search    
  Print page    
  

2010.05.30   Photocure announces US approval of Cysview(TM) for detection of bladder cancer  [Stock Exchange Notice]
2010.05.28   Photocure announces results from phase II study in acne with Visonac™  [Stock Exchange Notice]
2010.05.11   Photocure wins patent case against the US Patent and Trademark Office  [Stock Exchange Notice]
2010.04.28   1st quarter 2010 results  [Stock Exchange Notice]
2010.04.27   Åse Aulie Michelet foreslås som nytt styremedlem i Photocure  [Stock Exchange Notice]
2010.04.26   Presentation of the 1st quarter 2010 report  [Stock Exchange Notice]
2010.04.21   Expert panel recommends the use of Hexvix®-cystoscopy  [Stock Exchange Notice]
2010.04.07   Notice of annual general meeting  [Stock Exchange Notice]
2010.03.29   Annual Report 2009  [Stock Exchange Notice]
2010.03.18   Allotted Share Options  [Stock Exchange Notice]
2010.03.08   Shares purchased by employees and notification of trade  [Stock Exchange Notice]
2010.02.19   Presentation 4th Quarter 2009  [Stock Exchange Notice]
2010.02.19   Results 4th quarter and full year 2009  [Stock Exchange Notice]
2010.02.16   Presentation of the annual report 2009  [Stock Exchange Notice]
2010.01.13   Hexvix® receives reimbursement approval in Germany  [Stock Exchange Notice]
2010.01.06   Inclusion completed in phase II study with Visonac™ for acne  [Stock Exchange Notice]
2010.01.06   Financial calendar 2010  [Stock Exchange Notice]
2009.12.31   Photocure received positive response from FDA on the New Drug Application (NDA) for Hexvix® for detection of bladder cancer  [Stock Exchange Notice]
2009.12.18   FDA Advisory Committee voted favourably to Hexvix® application in USA  [Stock Exchange Notice]
2009.11.26   Photocure granted patent in Europe and Russia for Visonac™ in the treatment of acne  [Stock Exchange Notice]
2009.11.25   Extraordinary General Meeting  [Stock Exchange Notice]
2009.11.23   Shares purchased by employees  [Stock Exchange Notice]
2009.11.20   FDA has posted an Advisory Committee meeting with Photocure to discuss Hexvix® NDA  [Stock Exchange Notice]
2009.11.03   Notice of extraordinary general meeting  [Stock Exchange Notice]
2009.10.28   Capital Markets Day Presentations  [Stock Exchange Notice]


 
  Photocure ASA, Hoffsveien 48, NO-0377 Oslo, Norway. Telephone: +47 22 06 22 10 Fax: +47 22 06 22 18